What condition(s) is modafinil indicated for?

FDA-Approved Indications for Modafinil

Modafinil is FDA-approved to improve wakefulness in adults with excessive sleepiness associated with three specific conditions: narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWD). 1

Primary Approved Indications

1. Narcolepsy

• Modafinil carries a STRONG recommendation from the American Academy of Sleep Medicine for treating excessive daytime sleepiness in adult narcolepsy patients 2
• The drug is also recommended (conditional/weak) for pediatric narcolepsy, though FDA approval is limited to adults aged 17 and older 2, 1
• Typical dosing ranges from 200–400 mg daily, administered once upon awakening 2, 3

2. Obstructive Sleep Apnea (OSA)

• Modafinil is indicated only for residual excessive sleepiness in OSA patients who are already receiving optimal treatment for the underlying airway obstruction 1
• Critical limitation: Modafinil does not treat the airway obstruction itself and must be used as adjunctive therapy alongside continuous positive airway pressure (CPAP) or other primary OSA treatments 1
• Patients must continue their prescribed CPAP therapy; modafinil is not a replacement for mechanical airway management 1, 4

3. Shift Work Sleep Disorder (SWD)

• Modafinil improves night-time wakefulness in shift workers without disrupting subsequent daytime sleep 4
• The drug addresses excessive sleepiness during scheduled work hours but does not eliminate the need for adequate sleep hygiene 1, 5

Additional Strong Guideline-Supported Uses

Idiopathic Hypersomnia (Adults)

• The American Academy of Sleep Medicine issues a STRONG recommendation for modafinil as first-line pharmacotherapy in adult idiopathic hypersomnia 2
• This represents the only other condition with strong guideline support, though it is not explicitly FDA-approved

Conditional/Investigational Uses Mentioned in Guidelines

The American Academy of Sleep Medicine provides conditional (weak) recommendations for modafinil in:

• Hypersomnia secondary to Parkinson's disease 2
• Hypersomnia secondary to traumatic brain injury 2
• Hypersomnia secondary to myotonic dystrophy 2

These conditional recommendations reflect lower-quality evidence and require careful consideration of individual patient factors, comorbidities, and alternative treatments 2

Important Safety Limitations

Pediatric Use

• Modafinil is not FDA-approved for any indication in children under 17 years of age 1
• Serious dermatological toxicity (including Stevens-Johnson syndrome) occurs with greater frequency in pediatric populations, likely due to higher weight-based dosing 6

Controlled Substance Status

• Modafinil is a Schedule IV controlled substance (C-IV) due to potential for abuse and dependence 1
• However, actual abuse cases remain rare in clinical practice compared to traditional amphetamine-based stimulants 6, 5

Life-Threatening Adverse Reactions

• Serious rash, Stevens-Johnson syndrome, and multi-organ hypersensitivity reactions can occur and may be life-threatening even after drug discontinuation 1
• Patients must stop modafinil immediately if they develop rash, hives, mouth sores, facial swelling, difficulty swallowing, or signs of hepatic/hematologic toxicity 1

Common Pitfalls to Avoid

• Do not prescribe modafinil as monotherapy for OSA—the underlying airway obstruction requires mechanical treatment (CPAP, oral appliances, or surgery), and modafinil only addresses residual sleepiness 1
• Do not assume modafinil replaces adequate sleep—the drug improves wakefulness but does not eliminate the physiologic need for restorative sleep 1
• Do not overlook drug interactions—modafinil induces and inhibits multiple cytochrome P450 isoenzymes, reducing efficacy of hormonal contraceptives and interacting with numerous medications 1
• Do not use in patients with prior rash to modafinil or armodafinil—cross-reactivity is absolute and rechallenge risks severe cutaneous reactions 1